|
Trials
|
A
|
B
|
C
|
D
|
E
|
F
|
Total score (n/12)
|
|---|
|
Blonde 2016 [9]
|
2
|
2
|
1
|
2
|
2
|
1
|
10
|
|
Forst 2014 [10]
|
2
|
2
|
1
|
1
|
2
|
1
|
9
|
|
Neal 2015 [11]
|
2
|
1
|
2
|
2
|
2
|
1
|
10
|
|
Gonzalez 2013 [12]
|
2
|
2
|
1
|
2
|
2
|
1
|
10
|
|
Inagaki 2013 [13]
|
2
|
2
|
1
|
1
|
2
|
1
|
9
|
|
Inagaki 2014
|
2
|
1
|
1
|
1
|
2
|
1
|
8
|
|
Stenlof 2013 [15]
|
2
|
1
|
2
|
2
|
2
|
1
|
10
|
|
Wilding 2013 [16]
|
2
|
1
|
2
|
2
|
2
|
1
|
10
|
|
Yale 2013 [17]
|
2
|
1
|
2
|
2
|
2
|
1
|
10
|
|
Rosenstock 2012 [18]
|
2
|
1
|
2
|
2
|
2
|
1
|
10
|
- A: sequence generation; B: concealment of allocation; C: Blinding of patients; D: Blinding of caregivers; E: Blinding of outcome assessors; F: Follow-up and intention-to treat analysis
